Participated · Series A · Mar 2026

Poplar Therapeutics, incorporated in 2024 and based in Cambridge, Massachusetts, is focused on creating a new class of anti-IgE therapies that aim to rapidly drive IgE levels toward zero. Its lead candidate, PHB-050, employs a triple-action mechanism to block IgE binding to mast cells, quickly clear circulating IgE, and inhibit further IgE production. The drug is now in a Phase 1 clinical trial targeting food allergy, with data expected to demonstrate safety, pharmacokinetics, and speed of IgE reduction. Management plans to use forthcoming data to guide Phase 2 studies across multiple atopic conditions, including asthma and atopic dermatitis. Poplar estimates that more than seven million patients with atopic diseases have high IgE levels, half of whom with food allergy are poorly served by existing therapies. The company’s total Series A financing now stands at $95 million, providing resources to advance PHB-050 through at least Phase 2 trials.

Participated · Series C · Feb 2026

Founded in 2016, Skyryse is an El Segundo, California–based aviation automation company focused on SkyOS, a flight control operating system that replaces dozens of traditional gauges and switches with touchscreen-based automation. The system handles take-off, landing, hover, and engine-out emergencies, while still keeping a pilot in the loop, thereby enhancing safety and reducing pilot workload. Skyryse has already integrated SkyOS into platforms ranging from civilian helicopters to U.S. military Black Hawk helicopters and has inked integration contracts with United Rotorcraft, Air Methods, and Mitsubishi Corporation. The company is nearing the final stages of FAA certification after receiving final design approval for its flight control computers. New funding will accelerate SkyOS deployment across additional aircraft types and support the remaining certification testing. Including the latest round, Skyryse has secured more than $605 million in equity financing and now carries a $1.15 billion valuation.

Participated · Series C · Jun 2024

Frontier Medicines is a clinical-stage precision medicine company that leverages its proprietary Frontier Platform, a chemoproteomics-powered drug discovery engine using covalent chemistry and machine learning, to unlock hard-to-treat disease-causing proteins. The company is advancing a diversified pipeline of wholly-owned precision medicines focused on oncology and high-value immunology targets. Its lead candidate, FMC-376, is a dual ON+OFF KRASG12C inhibitor currently in the Phase 1/2 PROSPER trial (NCT06244771) and is designed to overcome resistance seen with single-acting KRASG12C inhibitors. Frontier has stated a goal of filing one IND per year as it progresses its programs. The company recently raised additional capital to support development of FMC-376 and to accelerate other preclinical and pipeline programs. Headquarters are listed as Boston and South San Francisco, California. Frontier Medicines is a clinical-stage precision medicine company based in Boston and San Francisco focused on therapies for genetically-defined patient populations in oncology and immunology. Its core product is the Frontier™ Platform, a chemoproteomics-empowered drug discovery engine that leverages covalent chemistry and machine learning to target hard-to-treat disease-causing proteins. The company is advancing a diversified pipeline of wholly-owned precision medicines, with lead candidate FMC-376, a dual inhibitor of on- and off-state KRASG12C. Frontier intends to use the new capital to advance multiple programs, including FMC-376, into clinical studies. The firm is led by CEO Chris Varma and emphasizes transforming treatment for genetically-defined patients. No revenue or user metrics were disclosed in the article. Frontier Medicines deploys integrated technologies in chemoproteomics, covalent drug discovery, and machine learning to generate medicines against proteins previously considered undruggable. The company is advancing a wholly-owned precision oncology pipeline, with a lead program that uniquely targets both the activated and inactive forms of KRASG12C. Frontier intends to use its platform to expand pipeline opportunities across therapeutic areas by leveraging identified protein hotspots. Proceeds from the recent financing are designated to advance research and development of its pipeline and to accelerate foundational technologies across chemoproteomics, covalent discovery, and machine learning. The company also announced a distinguished Scientific Advisory Board to support its programs and highlighted a substantial protein degradation partnership with AbbVie announced late last year. Frontier is expanding operations with a new Boston facility integrated with its South San Francisco headquarters to support bi-coastal growth and R&D capabilities. Frontier Medicines is a pre-clinical stage biopharmaceutical company developing medicines to redefine the course of debilitating diseases, starting with cancer. The company uses a proprietary chemoproteomics platform to chemically interrogate proteins in living systems and identify new binding pockets accessible to small-molecule drug discovery. Its platform also integrates advanced computational approaches and machine learning to accelerate drug discovery. Frontier intends to advance multiple therapeutic programs leveraging this platform. The company closed a $67M Series A to fund research and development, talent acquisition, and advancement of its platform and programs. Co-founders include Chris Varma (CEO), Roberto Zoncu, Ph.D., and Daniel K. Nomura, Ph.D.

Participated · Series C · May 2024

Zenas BioPharma is a clinical-stage biopharmaceutical company based in Waltham, MA, focused on inflammation and immunology-directed (I&I) therapies. Led by CEO Lonnie Moulder, the company operates clinical development capabilities globally and is advancing a portfolio of autoimmune therapeutics. Its lead candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcγRIIb to inhibit B cells, plasmablasts, and CD19-expressing plasma cells. Obexelimab is being evaluated across multiple programs, including a Phase 3 registration-directed trial in IgG4-Related Disease, two planned Phase 2 randomized controlled trials in Multiple Sclerosis and Systemic Lupus Erythematosus, and an ongoing open-label Phase 2 in Warm Autoimmune Hemolytic Anemia. The company intends to use new funding to advance ongoing mid- to late-stage clinical development programs for obexelimab and its broader I&I portfolio. Zenas BioPharma is a biopharmaceutical company focused on advancing and commercializing immune-based therapies. Led by Lonnie Moulder and based in Waltham, MA, its lead candidate is obexelimab, an investigational phase III‑stage bifunctional antibody that inhibits CD19‑expressing B‑cell lineages without depleting the cells. Zenas acquired exclusive worldwide rights to obexelimab from Xencor. In early‑stage clinical studies obexelimab demonstrated inhibition of B‑cell function and produced an encouraging treatment effect in patients with multiple autoimmune diseases. The company plans to use new funding to initiate a global Phase 3 registration trial in patients with IgG4‑related disease in late 2022 and to progress other global autoimmune disease programs into clinical development in 2023. IgG4‑RD is described in the article as a chronic, serious fibroinflammatory disease that typically affects multiple organs.

Participated · Equity · Feb 2024

Freenome develops blood-based screening tests for early cancer detection using a multiomics platform that combines computational biology, machine learning, and other technologies. Its initial programs focus on colorectal and lung cancers, with single-cancer and tailored multi-cancer tests under development. The platform is also being evaluated with biopharma and diagnostic partners to non-invasively detect minimal residual disease (MRD) augmented by biological insights. The company has registrational studies underway, including PREEMPT CRC (>40,000 participants) and PROACT LUNG (up to 20,000 participants), plus multi-cancer research programs such as the Vallania Study (more than 6,200 participants) and additional studies totaling >10,000 paired RWD participants. Freenome intends to use the newly raised funds to advance its pipeline of single-cancer and multi-cancer early detection tests. The company is led by CEO Mike Nolan and is based in San Francisco, CA. Freenome develops a multiomics platform that uses routine blood draws to detect cancer in its earliest stages. Its core product is a blood test for colorectal cancer (CRC) being validated in the large prospective registrational study PREEMPT CRC, which is nearing completion of enrollment. The company plans to commercialize the CRC screening test and expand the platform to detect other cancers, and has reported promising data in pancreatic cancer detection. Freenome combines molecular biology, computational biology, and machine learning to identify disease-associated patterns among circulating cell-free biomarkers. Financially, Freenome announced a $300M Series D and has raised over $800M in total financing since its 2014 founding. The new funding is intended to support commercialization and further development of multi-cancer tests. Freenome has developed a comprehensive multiomics platform to detect cancer early from a routine blood draw, beginning with a colorectal cancer screening test. The platform integrates genomics, transcriptomics, methylomics, and proteomics with advanced computational biology and machine learning to recognize disease-associated patterns among circulating cell-free biomarkers. Freenome launched the PREEMPT CRC FDA registrational clinical trial in May 2020 to support approval of its first front-line blood test for colorectal cancer screening and precancerous lesion detection. The company intends to use proceeds from the financing to accelerate PREEMPT CRC toward approval, reimbursement, and commercialization, advance a pipeline of blood tests for additional cancers, and continue building its proprietary multiomics platform. Financially, Freenome closed an oversubscribed $270 million Series C that brings total financing to over $500 million since the company’s launch. The company is headquartered in South San Francisco, California. Freenome has built a multiomics platform that integrates assays for cell-free DNA, methylation, and proteins with computational biology and machine learning to detect early signs of cancer from a routine blood draw. The company’s first test targets colorectal cancer and uses a multidimensional view of tumor- and immune-derived signatures to improve sensitivity and specificity. Freenome reported promising clinical results at Digestive Disease Week showing high sensitivity and specificity in a cohort of mostly early-stage colorectal cancer patients. The company plans a pivotal validation study and intends to submit to the FDA and CMS under the Parallel Review Program for its colorectal cancer screening application. Proceeds from its recent financing will also fund expansion of laboratory infrastructure and software to support growth and future development. Freenome is headquartered in South San Francisco and was founded in 2014. Freenome is a health-technology company combining machine learning, biology and computer science to develop non-invasive disease screening assays based on cell-free DNA and other analytes. The company has collaborated with more than 25 research partners, including UCSD Moores Cancer Center, UCSF and MGH, and has processed thousands of samples through research and clinical trials. Freenome is working with five pharmaceutical companies to validate its software for clinical trial stratification and precision prescribing. The company is focused on scaling its technology and improving screening accuracy for lung, colorectal, breast and prostate cancers, with plans to address additional cancers and diseases. Proceeds from the Series A financing are being used to accelerate clinical trials, expand research, and advance its first products toward regulatory review. Headquartered in South San Francisco and launched in 2014, Freenome has raised more than $70 million since founding.